Although targeting NMNAT in hemato-oncology seems a viable approach and tumor resistance acquisition (at least via alternative NAD+ production mechanisms) would not be anticipated, multiple factors should be taken into account during the development of NMNAT inhibitors. This evidence concerns the gene NMNAT1 and neoplasm.